Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

• Published in: Headache 2007-02, Vol.47 (2), p.170-180
• Main Authors: Silberstein, Stephen D., Lipton, Richard B., Dodick, David W., Freitag, Frederick G., Ramadan, Nabih, Mathew, Ninan, Brandes, Jan L., Bigal, Marcelo, Saper, Joel, Ascher, Steven, Jordan, Donna M., Greenberg, Steven J., Hulihan, Joseph
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; Biological and medical sciences; Cardiovascular system; chronic daily headache; Chronic Disease; clinical trial; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fructose - adverse effects; Fructose - analogs & derivatives; Fructose - therapeutic use; Humans; Male; Medical sciences; Middle Aged; migraine; Migraine Disorders - drug therapy; Muscle; Neurology; Pharmacology. Drug treatments; preventive treatment; topiramate; transformed migraine; Treatment Outcome; Vascular diseases and vascular malformations of the nervous system; Vasodilator agents. Cerebral vasodilators
• ISSN: 0017-8748; 1526-4610
• DOI: 10.1111/j.1526-4610.2006.00684.x

Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine. Methods.—This was a randomized, placebo‐controlled, parallel‐group, multicenter study consisting of 16 weeks of double‐blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of topiramate 25 mg/day (or placebo) was titrated upward in weekly increments of 25 mg/day to a maximum of 100 mg/day (or to the maximum tolerated dose). Concomitant preventive migraine treatment was not allowed, and acute headache medication use was not to exceed 4 days per week during the double‐blind maintenance period. The primary efficacy endpoint was the change from baseline in the mean monthly number of migraine/migrainous days; the change in the mean monthly number of migraine days also was analyzed. A fixed sequence approach (ie, gatekeeper approach) using analysis of covariance was used to analyze the efficacy endpoints. Assessments of safety and tolerability included physical and neurologic examinations, clinical laboratory parameters, and spontaneous reports of clinical adverse events. Results.—The intent‐to‐treat population included 306 (topiramate, n = 153; placebo, n = 153) of 328 randomized subjects who provided at least 1 efficacy assessment; 55.8% of the topiramate group and 55.2% on placebo were trial completers. The mean final topiramate maintenance dose was 86.0 mg/day. The mean duration of therapy was 91.7 days for the topiramate group and 90.6 days for the placebo group. Topiramate treatment resulted in a statistically significant mean reduction of migraine/migrainous headache days (topiramate −6.4 vs placebo −4.7, P= .010) and migraine headache days relative to baseline (topiramate −5.6 vs placebo −4.1, P= .032). Treatment‐emergent adverse events occurred in 132 (82.5%) and 113 (70.2%) of topiramate‐treated and placebo‐treated subjects, respectively, and were generally of mild or moderate severity. Most commonly reported adverse events in the topiramate group were paresthesia (n = 46, 28.8%), upper respiratory tract infection (n = 22, 13.8%), and fatigue (n = 19, 11.9%). The most common adverse events in the placebo group were upper respiratory tract infection (n = 20, 12.4%), fatigue (n = 16, 9.9%), and nausea (n = 13, 8.1%). Discontinuations due to adverse eve